Loading
Life sciences · Journal article
Psychosomatic Medicine · November 3, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Objective: This study investigated the association between depressive symptoms during the menopausal transition and subsequent incident type 2 diabetes (T2D), with particular focus on: (1) quantifying the mediating role of central obesity in this association, and (2) examining differential effects by depressive symptom subscales (somatic vs. cognitive/affective symptoms). Methods: We analyzed data from 1719 participants in the Study of Women’s Health Across the Nation, a multi-ethnic cohort study of midlife women. Depressive symptoms were assessed repeatedly using the Center for Epidemiologic Studies Depression Scale (CES-D). We calculated the total and subscales of depressive symptom burden during the menopausal transition. Causal mediation analysis within a counterfactual framework was employed to decompose the total effect between depressive symptoms and incident T2D during postmenopausal follow-up into natural direct effects (NDE) and indirect effects (NIE) mediated through central obesity measured at the first postmenopausal visit, adjusting for demographic, lifestyle, and health-related covariates. Results: During a mean postmenopausal follow-up of 11.60 (SD 3.58) years, 170 women (9.89%) developed T2D during follow-up. Central obesity mediated 21.4-23.5% of the total effect of depressive symptoms burden on T2D risk. Somatic subscales of CES-D scores showed strongest associations (OR=1.272 (95% CI:1.041-1.567) and NIE OR=1.100 (1.040-1.165)) in unadjusted models, with 21.3-25.0% mediated through central obesity after full adjustment. Cognitive/affective subscale showed weaker mediation effects (19.4-26.9%). Sensitivity analyses confirmed robustness to unmeasured confounding, with somatic symptom effects remaining significant under moderate confounding (NIE OR= 1.057 (95% CI:1.004–1.115)). Conclusions: Greater cumulative depressive symptom burden during the menopausal transition, particularly somatic subscales, was associated with higher odds of incident T2D after postmenopause, with part of the association mediated through central obesity at postmenopause. These findings highlight the menopausal transition as a critical period for interventions targeting both mental health and metabolic risk factors.